Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

By J. Rinehart, A. Adjei, P. LoRusso, D. Waterhouse, J. Hecht, R. Natale, O. Hamid, M. Varterasian, Peggy Asbury, E. Kaldjian and 5 more. Journal of Clinical Oncology, 2004

621 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/57947618874ecf9e7c707e407b7d73a232481902

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Der
2. P. Roberts
3. J. Baselga
4. S. Hagan
5. Nikolaus Schultz
6. Michael Mingzhao Xing
7. Walter Kolch
8. Oliver Rath

In Oncology

1. C. Der
2. P. Roberts
3. J. Baselga
4. Nikolaus Schultz
5. Walter Kolch
6. Gregory Riely
7. M. Hellmann
8. M. Callahan

Citations in the corpus

• MEK1 mutations confer resistance to MEK and B-RAF inhibition (2009, neutral): “Although early clinical trials of RAF and MEK inhibitors failed to show a substantial benefit (6, 7), recent phase I studies of selective RAF inhibitors have shown promising results in patients with BRAF-mutant tumors (8, 9).”
• Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “A Phase II study of patients with advanced pancreatic, breast, colon and nonsmall cell lung cancers [52], but none of the patients achieved a complete, or partial response, and only eight patients had stabilization of disease (median of 4.”
• OncoKB: A Precision Oncology Knowledge Base (2017, methodology): “…the randomized phase 2 study that supplemented standard chemotherapy with a MEK inhibitor 73 , the subsequent phase 3 trial showed no survival benefit with this combination 74 , consistent with negative data associated with MEK inhibitor use in KRAS-mutant pancreatic and colorectal cancers 75,76 .”
• BRAF mutation in thyroid cancer. (2005, background): “Endocrine-Related Cancer (2005) 12 245–262”
• Targeting the mitogen-activated protein kinase cascade to treat cancer (2004, background): “CI-1040 has been evaluated in Phase I and Phase II trial”
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “Subsequent phase I and II clinical trials reported the most common toxicities were mild skin rash, diarrhea and fatigue (Lorusso et al., 2005) (Rinehart et al., 2004).”
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. (2008, background): “9, 10,16 Seven patients developed transient and reversible blurred vision while receiving AZD6244, an adverse effect also observed with PD0325901 and CI-1040.”
• MAP kinase signalling pathways in cancer (2007, background): “Hopes are now on PD0325901, a secondgeneration MEK1/2 inhibitor, with improved pharmaceutical and pharmacological properties (Rinehart et al., 2004).”